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Chronic peripheral inflammation in diseases such as rheumatoid arthritis leads to alterations in central pain processing
and consequently to mood disorders resulting from sensitization within the central nervous system and enhanced
vulnerability of the medial pain pathway. Proinflammatory cytokines such as tumor necrosis factor (TNF) alpha play an
important role herein, and therapies targeting their signaling (i.e., anti-TNF therapies) have been proven to achieve
good results. However, the phenomenon of rapid improvement in the patients’ subjective feeling after the start of
TNFα neutralization remained confusing, because it was observed long before any detectable signs of inflammation
decline. Functional magnetic resonance imaging (fMRI), enabling visualization of brain activity upon peripheral immune
stimulation with anti-TNF, has helped to clarify this discrepancy. Moreover, fMRI appeared to work as a reliable tool for
predicting prospective success of anti-TNF therapy, which is valuable considering the side effects of the drugs and
the high therapy costs. This review, which is mainly guided by neuroimaging studies of the brain, summarizes the
state-of-the-art knowledge about communication between the immune system and the brain and its impact on
subjective well-being, addresses in more detail the outcome of the abovementioned anti-TNF fMRI studies (rapid
response to TNFα blockade within the brain pain matrix and differences in brain activation patterns between
prospective therapy responders and nonresponders), and discusses possible mechanisms for the latter phenomena
and the predictive power of fMRI.Peripheral-to-central communication
In the last few decades, a large body of knowledge has
been accumulated regarding bidirectional communi-
cation between the immune system and the brain (for
review see [1–7], for historical overview of the discoveries
see [8]). A new branch of research, psychoneuroimmun-
ology has emerged primarily from the great interest in the
role of the immune system in neuropsychiatric disorders,
especially major depression. Much attention has been
attracted following the discovery that increased peripheral
inflammation is associated with depression and fatigue
[3–6, 9–13]. Noteworthy is the frequent occurrence of
depression in patients with rheumatoid arthritis (RA) and
infectious and autoimmune diseases [14–16], and, in-
versely, there are elevated concentrations of inflammatory* Correspondence: andreas.hess@fau.de
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sion. These findings stimulated further investigation of
mechanisms by which inflammatory information is trans-
mitted from the periphery to the central nervous system
(CNS). It is now known that proinflammatory cytokines,
in particular interleukin (IL)-1, IL-6, and tumor necrosis
factor (TNF) alpha, are important transmitters of this
information. IL-6 and TNFα appeared to be the most
consistently elevated cytokines in the studies conducted
on depressive patients (see meta-analysis [10]) as well as
in animal models of depression [17]. Released when con-
fronted with an immune challenge—infection, injury, or
stress—or externally administered (e.g., interferon alpha in
the case of cytokine therapy), cytokines not only trigger
cascades of defensive responses on molecular and cellular
levels, but also act on an organismic level. The cytokines
instruct the CNS how it should adapt its behavior to the
altered conditions or, in other words, how to conserve
energy for the purpose of optimal recovery [18].le is distributed under the terms of the Creative Commons Attribution 4.0
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social factors such as stress [5, 6, 11, 20–23] or “social
pain” [24], also promoting the development of depression.
Peripheral cytokine signals reach the brain via three
principal pathways—humoral, neural, and cellular—via
several mechanisms [4, 5] including (adapted from [5]):
passage through leaky regions in the blood–brain barrier
at circumventricular organs; active uptake across the
blood–brain barrier; the “neural route” via local actions
at peripheral vagal nerve afferents that relay cytokine
signals to relevant brain regions, including the nucleus
of the solitary tract and hypothalamus, and directly at
sensory neurons; activation of endothelial cells and
perivascular macrophages in the cerebral vasculature
to produce local inflammatory mediators such as
cytokines, chemokines, prostaglandin E2 (PGE2), and
nitric oxide (NO); and recruitment of activated monocytes/
macrophages and T cells from the periphery. A poten-
tial gateway for immune cells into the brain has been
discovered recently: functional lymphatic vessels lining
the dural sinuses [25]. Within the brain, peripheral cy-
tokines act on a central network of microglia, astro-
cytes, and neurons, which in turn produce cytokines
[26]. This can amplify cytokine signals. Cytokines acti-
vate the hypothalamic–pituitary–adrenal axis, stimu-
lating the production of corticotropin-releasing factor,
adrenocorticotropic hormone, and cortisol [1], and in-
fluence many other physiological processes in the CNS.
The cytokines alter the metabolism of neurotransmit-
ters serotonin [27, 28], dopamine [28–31], glutamate
[32, 33], which in turn leads to decreased production of
the trophic or growth factors necessary for neurogen-
esis and neuroplasticity [6, 34, 35], or norepinephrine
[5, 6]. Many studies demonstrated reduction of brain
matter, especially in hippocampus [19, 35–37], but also
different alterations in other areas of the brain [38–43]
under continuously elevated IL, or changes in func-
tional connectivity [43–48]. The latter can best be
encompassed by functional neuroimaging methods and
will be discussed in a separate section.
Rapid onset of behavioral consequences
Multiple studies on humans and on experimental ani-
mals with elevated levels of proinflammatory cytokines
in the periphery report in their subjects the so-called
“sickness behavior” [49, 50]. This phenomenon has been
well described and implicates, depending on the severity
of the disturbance, such symptoms as fatigue, psycho-
motor slowing [22, 29], anxiety, anhedonia [51], cogni-
tive dysfunction [52] (for review of the role of cytokines
in maintaining the normal cognitive function see [53]),
social withdrawal [54], sleep alterations, and loss of ap-
petite, in different combinations. Notably, the sickness
behavior develops very rapidly. Frenois et al. [55], usinga range of behavioral tests, distinguished two phases and
characterized their time development in mice injected
with lipopolysaccharide (LPS). The authors have shown
that sickness behavior peaked after 6 h, followed by the
depressive-like behavior 24 h post LPS. The latter was
paralleled by a decrease in cellular activities, particularly
within the extended amygdala, hippocampus, and hypo-
thalamus as shown by immunohistochemistry. Stone
et al. [56] revealed that the exploratory movement ac-
tivity of mice injected with LPS was reduced a mere 2 h
post treatment. Similar timing was described in studies
on healthy humans using, for example, Salmonella typhi
vaccine as an inflammatory challenge [22, 29, 57–59].
Vaccination with S. typhi appears to be an appropriate
model for investigation of depressive symptoms not
superimposed by actual disease burden; it does not in-
duce sickness. In these studies, deterioration of mood
was observed starting within 3 h and lasting for at least
6 h after injection.
Normally the release of proinflammatory cytokines is
adaptive and temporary, and so are its consequences as
already described. Quite a different situation arises if a
cytokine challenge becomes chronic; for example, in
cases of chronic inflammatory diseases or permanent
stress [18]. In these cases, in addition to the known
primary symptoms, we can expect the development of
clinically relevant psychiatric disorders such as major
depression.
Rheumatoid arthritis and TNFα
RA is a chronic autoimmune inflammatory disease
severely affecting the joints. As the disease progresses,
RA rapidly leads to destruction of cartilage and bone
tissue, which is associated with pain, swelling, stiffness,
and even immobility of the joints. Quality of life for
people suffering from RA is dramatically diminished,
and pain is the prevailing symptom of this disease.
Treatment of RA was extremely challenging before the
development and introduction of drugs inhibiting bio-
logical activity of TNF (anti-TNF therapies). While
affected joints express a multitude of inflammatory me-
diators, systemic inhibition of TNFα turned out to be a
particularly successful therapeutic strategy [60–62]. This
success is based in part on the efficient alleviation of
joint inflammation upon disruption of the inflammatory
cytokine network in the affected joint. However, it has
always been surprising how quickly the patient condition
improves taking into account that RA causes irreversible
structural damage to the bones, the cartilage, and the
joint innervation pattern [61, 63]. Nevertheless, amelior-
ation of pain and improvement of personal subjective
feeling set in soon after the start of TNF neutralization,
long before inflammation decline becomes identifiable
using common clinical tests.
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independent, faster impact of TNF inhibition on the
CNS. Do anti-TNF therapies elicit pain-reducing effects
in the central pain pathway? Consequently, functional
brain imaging studies have been conceived to in-
vestigate changes in brain function—pain processing in
particular—under TNFα inhibition.
Functional neuroimaging: impact of cytokines on
brain functions
Neuroimaging methods have brought new oppor-
tunities for linking fields of medicine operating at
different levels; that is, immunology and neurology
[19, 21, 24, 29, 48, 54, 57, 58, 64, 65] (for review see
[38]). In particular, neuroimaging has revealed individual
brain structures, but also complex neurocircuits in the
CNS that appear to be modulated by cytokine signaling
from the periphery; for instance, the anterior cingulate cor-
tex (ACC), the basal ganglia, including nucleus accumbens,
striatum, and substantia nigra, and the insular cortex. Sub-
genual ACC plays an important role in depression, and dor-
sal ACC in anxiety and alarm. Basal ganglia are essential for
motor activity and also for motivation. The insular cortex is
strongly linked to the emotional state (particularly its anter-
ior, limbic-related portion), self-awareness, and empathy,
and plays an important role in the regulation of the body’s
homeostasis.
Vaccination with S. typhi was paralleled by increased acti-
vation in subgenual and dorsal ACC, as demonstrated by
functional magnetic resonance imaging (fMRI), and a de-
terioration in mood and anxiety [57]. In subjects vaccinated
with S. typhi, perturbed activity in the substantia nigra was
associated with an increase in the amount of time required
to solve a cognitive task, consistent with the notion that cy-
tokines influence dopamine transmission [30, 51], and also
correlated with increased levels of IL-6 in the blood [29].
Persons injected with Escherichia coli endotoxin exhibited
increases in depressed mood and anhedonia over time, cor-
related with a significant reduction of activity in the ventral
striatum, part of the reward circuit, evoked by monetary re-
ward cues [51]. Women exposed to E. coli endotoxin be-
came more vulnerable to social exclusion and, in a similarly
structured fMRI study, exhibited increased activity in dorsal
ACC and anterior insula paralleled to an elevation of IL-6
in blood and to a deterioration in mood [24]. Functional
connectivity of the insula has been shown to increase under
inflammatory conditions [47].
General evidence from functional neuroimaging sug-
gests that two main mechanisms may be largely res-
ponsible for clinical pain in rheumatic diseases: CNS
sensitization/impairment of inhibition; and alterations in
the medial pain system (for review see [38]), which is
responsible for the affective-motivational pain compo-
nent (Fig. 1).fMRI prediction ahead of clinical evidence
Using fMRI, we [45] addressed the question of the rapid
improvement of RA patients’ disease state following the
start of TNF neutralization by anti-TNF. The rationale
of the investigation was as follows. Given that TNFα also
acts as a pain mediator, we hypothesized that during RA
the cytokine constantly changes pain processing in the
CNS. Systemic inhibition of TNFα should thus positively
influence central pain processing, and this may happen
long before it affects joint inflammation. Using blood
oxygen level-dependent (BOLD) fMRI we measured the
network of brain structures in RA patients activated in
response to nociceptive stimulation of the affected joints
before and at various points in time after intravenous in-
fusion of infliximab, an anti-TNFα monoclonal antibody.
Nociceptive activity in the brain pain matrix was sig-
nificantly reduced as quickly as 24 h after TNF neu-
tralization. This activity remained low until the end of the
observation period 42 days after anti-TNF administration.
BOLD activity decreases were observed in thalamus and in
primary and secondary somatosensory cortices—structures
responsible for the sensory-discriminative aspect of
pain—but also to a large extent in parts of the limbic
system, such as the cingulate and insular cortex, which are
responsible for the affective-motivational or emotional
pain component. Importantly, standard clinical measures
of the disease activity—joint swelling and joint tenderness,
composite disease activity scores (Disease Activity Score
in 28 joints), and laboratory parameters such as the blood
sedimentation rate and serum C-reactive protein and IL-6
levels—did not change within the first 24 h, but improved
at a later stage of the treatment process. In contrast,
subjective perception of pain in these patients, judged ac-
cording to the visual analog scale (VAS), was ameliorated
as early as 24 h after the first infusion, in parallel with the
changes of nociceptive activity in the brain detected by
fMRI.
These findings have been further substantiated by in-
vestigation into an animal model of arthritis: knockin
mice overexpressing human TNFα (hTNFtg) [66]. Be-
havioral screening of these hTNFtg mice demonstrated
that these animals develop characteristic signs of arth-
ritis; for example, bone degeneration [61, 63] and de-
creased mobility [45]. Similar to humans, 24 h after
treatment with infliximab arthritic mice showed signifi-
cantly diminished sensitization to noxious stimuli, as has
been established by von Frey as well as Hargreaves’ tests,
which remained at the level of wild-type mice for at least
72 h. During the first 24 h following TNF neutralization,
no apparent changes to clinic analog parameters or
histopathologic signs of arthritis were observed. Remark-
ably, TNFα inhibition also completely restored motor ac-
tivity (indicative of good mood), as demonstrated by the
Rotarod test, within 24 h.
Fig. 1 Schematic representation of the pain system and pathways for the influence of cytokines on brain function. Pain is a multidimensional
sensation initiated at pain receptors in the periphery (nociceptors) by (potentially) harmful stimuli. The pain system consists of ascending and
descending pathways which are highly interconnected at different processing stages up to the prefrontal cortex (PFC) as the highest station of
nociceptive processing and a central hub of the cognitive dimension of pain. The most important transfer and “preprocessing” stations of nociceptive
information are: the spinal cord (dorsal horn neurons), the brainstem including among others the medulla oblongata and peri-aqueductal grey (PAG),
and the thalamus. From there and upwards one differentiates between two functionally overlapping but basically different subsystems. The lateral
thalamus (LT) projects to the primary and secondary somatosensory cortices (SSC). These structures constitute the so-called lateral pain system
responsible for the sensory-discriminative dimension of pain. The medial thalamus (MT) has tight connections to the anterior cingulate cortex (CC) and
further to the PFC. These structures form the medial pain system considered to be in charge of the affective-motivational dimension of pain. Moreover,
this system has extensive interconnections with the limbic system—entorhinal cortex, hippocampus (Hip), amygdala (Amy)—which is inseparably
associated with emotions. The insular cortex has an intermediate position since it receives somatosensory input (posterior part, PIns), but has strong
reciprocal connections to the amygdala (anterior part, AIns). Therefore, the insula can be ascribed to the medial pain system. As an “output” of pain
processing, structures for immediate motor and autonomic responses and pain control are activated. Motor responses originate in the PFC, in higher
order motor cortices and next in the primary motor cortex (MotC). They send downstream commands to the motor neurons in the spinal cord. The
motor thalamus (MotT) and the motor basal ganglia dorsal striatum (DS) and cerebellum (Cer) take part in coordination of the motor responses. The
other compartment of the basal ganglia, the ventral striatum (VS), belongs to an associative-limbic loop forming a link to the motor system influenced
by motivational and emotional context. The hypothalamus (HT) orchestrates neuroendocrine and autonomic responses to pain. One of the most
important elements of the descending inhibitory pain control acts via the PAG upon the dorsal horn neurons. Proinflammatory cytokines (IL-6, IL-1β,
TNFα) reaching the brain exert powerful influence on the neurocircuits related to the affective-motivational dimension of pain and interfere with
multiple physiologic processes relevant to mood regulation in the entire brain (see “Peripheral-to-central communication”). IL interleukin, TNF tumor
necrosis factor
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designed in a way which is possibly similar to the study
of RA patients. As a response to nociceptive stimuli, be-
fore treatment, one could see significantly greater activa-
tion in the brain pain matrix of these mice comparedwith the wild-type mice. TNFα neutralization with inflix-
imab led to a drastic reduction in this activity down to
the level of wild-type mice (even lower in limbic areas)
within 24 h. Again, there were profound decreases not
only in the somatosensory cortex (sensory-discriminative
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system (emotional aspect).
Our research group [45] came to the conclusion that
TNFα inhibition has a direct impact on central pain pro-
cessing by far preceding its anti-inflammatory effects at
the periphery. Suppression of neuronal activity in the
limbic brain areas, in the cingulum and insula, could
well explain the fast improvement of the subjective pain
rating and overall feeling of RA patients following TNF
neutralization. Therefore, one can speculate that anti-
TNF also exhibits rapid antidepressant effects.
BOLD fMRI has been proven capable of issuing an
early prediction of therapeutic success for TNF inhib-
ition. This advantage of fMRI is especially valuable in
light of the following dilemma: on the one hand, TNF
blockers are expensive drugs with a potential risk for
serious toxicity; and on the other, they have been shown
to be highly effective, although not in all patients suf-
fering from RA. To further investigate whether fMRI
can also be used to differentiate between prospective re-
sponders and nonresponders to anti-TNF, we undertook
a follow-up investigation [67]. In the follow-up investi-
gation, RA patients received a standard injection of
certolizumab-pegol, a subcutaneously administered anti-
TNF, and fMRI measurements with the same stimulation
paradigm as in the previous study [45] were performed
before treatment and at several points in time after treat-
ment. Clinical parameters were assessed at the same time
points, as well as patients’ rating of global disease activity
by VAS. In this study, similarly to clinical practice, one-
half of the patients exhibited a significant clinically identifi-
able improvement after 28 days (responders), while the
other half did not (nonresponders), although initial clinical
baseline disease activity did not differ between the two
groups. In accordance with the previous findings, the re-
sponder group demonstrated rapid (detectable on the third
day) reduction of nociception-related activity in the brain
pain matrix, which continued consistently over the follow-
ing fMRI measurements. In the nonresponder group, in
contrast, there was only a spurious decrease of the BOLD
activity after 3 days, which then increased back to the ini-
tial levels after 7 and 28 days. A remarkable finding in this
study was the striking difference in the number of signifi-
cantly activated voxels under the nociceptive stimulation
between the two groups before treatment: this number
was high in the responders and low in the nonre-
sponder group, particularly in the somatosensory, lim-
bic, and associative brain areas. This study shed even
more light on the predictive power of fMRI; the qualita-
tive difference in the mean value of BOLD activation
between the potential responders and nonresponders to
anti-TNF was obvious even before treatment. As a next
step, the quantitative determination of a threshold be-
tween responders and nonresponders is currently beingperformed in a clinical phase III multicenter study
(PreCePRA NCT01864265).
Discussion
Chronic inflammation occurring in RA and many other
diseases triggers a continuous flow of afferent signals to
the brain causing, among other things, chronic pain
states. Central sensitization to these afferent stimuli and
alterations in the medial pain system present as a result
of chronic pain seem to be some of the main features of
pathological sensory signaling in the CNS caused by
inflammation [38]. RA is burdened with a profound
affective-emotional aspect implicating fatigue, sleep im-
pairment, and depressive mood. If TNF inhibitors exert,
in addition to their anti-inflammatory effects at the per-
iphery, a direct normalizing influence on central pain
processing, then the fast relief reported by the patients
following the commencement of anti-TNF therapy is not
particularly surprising, since the standard clinical judg-
ments in RA (VAS for pain, Disease Activity Score in 28
joints, Health Assessment Questionnaire and the quality-
of-life instrument Short Form 36) are based on the
patient’s subjective perception, rather than on objective
parameters of the disease [68]. Objective measures of this
direct normalizing influence were shown in the two clin-
ical experimental studies [45, 67], albeit with a limited
number of subjects included. The studies confirmed that
neutralization of the proinflammatory cytokine TNFα
rapidly improves the subjective state of the prospective
responder RA patients and demonstrated that this im-
provement is associated with a drastic reduction in
nociception-related activity within the brain pain matrix;
the latter not only in the structures responsible for the
sensory-discriminative component of pain, but im-
portantly to a large extent also in the structures driving its
affective-motivational aspect and involved in mood chan-
ges, including depression, and memory. BOLD fMRI of
the brain has demonstrated potential ability to predict the
therapeutic success of TNF inhibition at an early stage in
the course of treatment [45] and possibly even before
treatment is commenced [67]. One can hypothesize that
the response to anti-TNF therapy depends on patients’
subjective disease perception which is reflected in the in-
dividual brain activity pattern. Could this statement
equally be assigned to disorders other than RA caused by
chronic inflammation?
Neutralization of TNFα was shown to be highly effective
in treating the other complex diseases such as psoriasis
[69] and Crohn’s disease [70–73], with a profound impact
on depressive mood. Remarkably, in these diseases an im-
provement in the symptoms also occurs before inflamma-
tion remission becomes clinically identifiable. Psoriasis
patients who received etanercept (a soluble TNF receptor
that prevents TNFα-mediated responses by competitively
Note: This article is part of the series ‘At the interface between
immunology and neurology in rheumatic diseases’, edited by Rainer
Straub. Other articles in this series can be found at
http://arthritis-research.com/series/neurology.
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tors) exhibited a significant improvement in fatigue and
depression, the former correlated with and the latter not
correlated with objective measures (skin clearance or joint
pain) [69]. Etanercept also has been successful in reducing
fatigue in cancer patients [74].
Fascinating parallels can be seen between the findings
of the follow-up RA fMRI study [67] and a Crohn’s dis-
ease study by Atreya et al. [72]. The authors of the latter
study managed an early prediction of the therapeutic
success of adalimumab (TNF antibody) in patients with
this disorder. Like in RA, in spite of the clinical efficacy
of anti-TNF treatment, about 50 % of patients with
Crohn’s disease do not respond to adalimumab, as deter-
mined by lack of a 100-point reduction of the clinical ac-
tivity score (Crohn’s disease activity index) within
4 weeks after therapy initiation [70]. With the help of
in-vivo imaging using a fluorescent TNF antibody, the
researchers [72] visualized intestinal immune cells carry-
ing membrane-bound TNF (mTNF). With respect to the
number of mTNF(+) cells, the patients, as in the RA
study, were split into two distinct clusters: in one of the
clusters this number was large, and in the other the
number of mTNF(+) cells was small. During the course
of therapy, again as in the RA study, the former turned
out to be responders—and their response was sustaina-
ble—and the latter turned out to be nonresponders.
Moreover, in full accordance with the RA studies [45,
67], a recent fMRI investigation of Crohn’s disease pa-
tients [73] confirmed that TNF neutralization with
infliximab rapidly improved the subjective state of the
prospective responders and demonstrated that this im-
provement was paralleled by a drastic reduction in
nociception-evoked activity within the brain pain matrix
as early as 24 h after the first injection, again by far pre-
ceding peripheral anti-inflammatory effects such as mu-
cosal healing.
If the patient’s reflections of the abovementioned dis-
orders in the brain have an important contribution to
the overall disease state, and TNF blockers do indeed
exert quick antidepressant effects, then there is hope
that fMRI could also help in predicting the anti-TNF
treatment outcome in these diseases.
Conclusion
CNS effects of cytokine blockers may, of course, differ
among various diseases. Individual cytokine blockers
might possess unique properties in modulating brain func-
tion; for example, IL-1 blockade leads to improvement of
fatigue in patients with Sjögren’s syndrome and diabetes
mellitus, whereas TNF blockade does not [75–77]. In
contrast, despite effects on fatigue [78] and potent anti-
inflammatory properties, IL-1 blockade has not resulted in
comparable improvement of composite disease activityindices in RA as compared with anti-TNF treatment. It is
plausible that each of these cases implicates unique
changes in the brain pain matrix and would thus be differ-
entially encompassed with fMRI. Furthermore, innate lim-
itations of the BOLD fMRI method should also be taken
into account. For instance, the technique cannot always
strictly differentiate between the direct impact of a therapy
on the affective-motivational aspect of pain processing
and the “secondary” impact, mediated via the sensory-
discriminative pain pathway. A degree of caution is re-
quired when interpreting the data. Nevertheless, it is more
than tempting to explore the capabilities of the noninva-
sive, fast, and spatially highly resolved fMRI method to
validate and to predict the therapeutic success over a
broader range of chronic inflammatory disorders and
cytokine-targeting therapies.Abbreviations
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